What does DiaMedica Therapeutics Inc. do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of…
What is DiaMedica Therapeutics Inc.'s P/E and P/B ratio?
DiaMedica Therapeutics Inc. has a P/E ratio of -12.0 and a P/B ratio of 12.14.
What is DiaMedica Therapeutics Inc.'s debt-to-equity ratio?
DiaMedica Therapeutics Inc. has a debt-to-equity ratio of 0.00.
How much does DiaMedica Therapeutics Inc. owe compared with what it owns?
DiaMedica Therapeutics Inc. owes $0.15 for every $1 it owns (balance sheet Jun 2026), which is low.
What is DiaMedica Therapeutics Inc.'s Positivity rank?
DiaMedica Therapeutics Inc. is ranked #5,845 of 6,775 companies globally and #3,253 of 4,000 in United States on PositoAI, with a Positivity Score of 14,886.
Does DiaMedica Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for DiaMedica Therapeutics Inc..
Where can I read the latest news about DiaMedica Therapeutics Inc.?
Recent headlines about DiaMedica Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does DiaMedica Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of DiaMedica Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.